Astria Therapeutics (Astria Therapeutics) EPS (Diluted) : $-2.40 (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Astria Therapeutics EPS (Diluted)?

Astria Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.38. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.40.

Astria Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.38. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.40.

Astria Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-0.38. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.40.

During the past 3 years, the average EPS without NRIGrowth Rate was 46.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 41.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 38.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, Astria Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 52.70% per year. The lowest was -2.00% per year. And the median was 43.55% per year.

Astria Therapeutics EPS (Diluted) Historical Data

The historical data trend for Astria Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astria Therapeutics EPS (Diluted) Chart

Astria Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-14.10

-12.20

-24.58

-3.55

-2.42

Astria Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Diluted)	Get a 7-Day Free Trial															-0.40	-0.45	-0.63	-0.94	-0.38

Competitive Comparison of Astria Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Astria Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astria Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Astria Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Astria Therapeutics's PE Ratio falls into.

Astria Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Astria Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-72.891	-	0)	/	30.123
	=	-2.42

Astria Therapeutics's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-19.928	-	0)	/	52.295
	=	-0.38

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.40

Astria Therapeutics (NAS:ATXS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Astria Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Astria Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Astria Therapeutics (Astria Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Astria Therapeutics Inc (NAS:ATXS) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 State Street, Suite 1400, Boston, MA, USA, 02109

Website

https://www.astriatx.com

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

Executives

Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrea Matthews	officer: Chief Business Officer	C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400, BOSTON MA 02109
Christopher Morabito	officer: Chief Medical Officer	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Andrew Komjathy	officer: Chief Commercial Officer	CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B14202, CAMBRIDGE MA 02139
Andrew John Nichols	officer: Chief Scientific Officer	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG 1400E, CAMBRIDGE MA 02139
Perceptive Xontogeny Venture Fund, Lp	director, 10 percent owner	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Jonathan Violin	director	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Fred Callori	director	100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Xontogeny, Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joanne T. Beck	director	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ, BLD. 1400E, SUITE B14202, CAMBRIDGE MA 02139
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Hugh M Cole	director	C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Benjamin Harshbarger	officer: Secretary and General Counsel	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142